The whole-body deletion or pharmacological inhibition of TMEM176B in murine cancer models decreased tumor growth through enhanced anti-tumor T cell immunity and improved the response to immune checkpoint inhibitors [4,10]. The gene discussed is TMEM176B; the disease is cancer.